Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Delpacibart zotadirsen in Exon 44 Skipping Mutation Duchenne Muscular Dystrophy: NCT05670730 Clinical Landscape Report 2026
28 September 2026
NCT05670730 clinical landscape for Exon 44 Skipping Mutation Duchenne Muscular Dystrophy: endpoints, sponsor, phase, geography, readouts, asset context and d…
9 min read
Simoctocog alfa in Hemophilia A: NCT05935358 Clinical Landscape Report 2026
28 September 2026
NCT05935358 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etranacogene dezaparvovec in Hemophilia B: NCT06003387 Clinical Landscape Report 2026
28 September 2026
NCT06003387 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Simoctocog alfa in Hemophilia A: NCT05936580 Clinical Landscape Report 2026
28 September 2026
NCT05936580 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TU-7710 in Hemophilia B: NCT06025552 Clinical Landscape Report 2026
28 September 2026
NCT06025552 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zemocimig in Hemophilia A: NCT05987449 Clinical Landscape Report 2026
28 September 2026
NCT05987449 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant Human Coagulation Factor VIIa-Fc Fusion Protein (Jiangsu Gensciences) in Hemophilia B: NCT06010953 Clinical Landscape Report 2026
28 September 2026
NCT06010953 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Calcium Phosphate in Hemophilia A: CTRI/2023/10/059237 Clinical Landscape Report 2026
28 September 2026
CTRI/2023/10/059237 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BBM-H803 in Hemophilia A: NCT06111638 Clinical Landscape Report 2026
28 September 2026
NCT06111638 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ANB-2 in Hemophilia B: NCT06120582 Clinical Landscape Report 2026
28 September 2026
NCT06120582 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KL-001 in Hemophilia B: NCT06119659 Clinical Landscape Report 2026
28 September 2026
NCT06119659 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efmoroctocog alfa biosimilar(AryoGen Pharmed) in Hemophilia A: NCT06137092 Clinical Landscape Report 2026
28 September 2026
NCT06137092 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.